NASDAQ · Biotechnology

BEAM (BEAM) Stock

$25.62 +2.19% NASDAQ: BEAM Healthcare

Valuation

MetricValue
Price$25.62
Market Cap$2.64B
P/E Ratio-35.36
P/B Ratio2.38
P/S Ratio17.96
EPS (TTM)$0.00
52-Week High$37.92
52-Week Low$15.60
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE-6.46%
ROA-5.40%
ROCE-31.02%
Gross Margin-273.57%
Operating Margin-274.29%
Net Margin-39.66%
Debt/Equity0.22
Current Ratio13.08

Annual Financials (USD)

Metric20212022202320242025
Revenue$52.0M$61.0M$378.0M$64.0M$140.0M
Operating Profit$-392.0M$-338.0M$-176.0M$-416.0M$-384.0M
Net Profit$-371.0M$-289.0M$-133.0M$-377.0M$-80.0M
EPS$-5.77$-4.13$-1.72$-4.58$-0.81
Op Margin-757.0%-555.6%-46.7%-654.3%-274.6%

Balance Sheet (USD)

Metric20212022202320242025
Total Assets$1.5B$1.3B$1.5B$1.1B$1.5B
Total Liabilities$648.0M$608.0M$478.0M$370.0M$243.0M
Cash$560.0M$233.0M$436.0M$282.0M$295.0M
Borrowings$148.0M$179.0M$173.0M$161.0M$294.0M

Latest News

Kyverna Therapeutics Sinks 13%: Here’s Why 24/7 Wall St. · Jul 10, 2026 Beam Therapeutics (BEAM) Faces New AATD Rival PM647 Ruling What Does It Signal Strategically? Simply Wall St. · Jul 9, 2026 NTLA Surges 38% in a Month: Should You Buy, Sell or Hold the Stock? Zacks · Jul 9, 2026 Gene Editors, Including Powerhouse Beam Therapeutics, Diverge On Legal Battle Investor's Business Daily · Jul 8, 2026 Update: Prime Medicine Receives Favorable Ruling in Beam Therapeutics License Arbitration; Shares Rise MT Newswires · Jul 8, 2026

Cash Flow (USD)

Metric20212022202320242025
Operating Cash Flow$-66.0M$23.0M$-149.0M$-347.0M$-345.0M
Investing Cash Flow$-341.0M$-510.0M$38.0M$176.0M$-136.0M
Financing Cash Flow$1.0M$6.0M$9.0M$0$0
Net Cash Flow$396.0M$-327.0M$199.0M$-155.0M$12.0M
Free Cash Flow$-113.0M$-26.0M$-183.0M$-356.0M$-360.0M

Valuation & Return Ratios

MetricValue
PEG Ratio—
EV / EBITDA—
FCF Yield-13.03%
Quick Ratio16.99
Interest Coverage-8.73
Return 1Y23.68%
Return 3Y-16.93%
Return 5Y-71.16%

Ownership

Insiders Held1.40%
Institutions Held106.90%
Institutions Float Held108.41%
Institutional HolderSharesReport Date
FMR, LLC12,452,1992026-03-31
ARK Investment Management, LLC12,133,4332026-03-31
Farallon Capital Management LLC10,134,6962026-03-31
Blackrock Inc.8,487,5692026-03-31
State Street Corporation5,699,2652026-03-31

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
AGIO $31.72 +0.38% -3.56 $1.89B 0.00%
COGT $42.27 -1.33% -34.70 $7.22B 0.00%
DNLI $24.42 +1.03% -6.20 $3.88B 0.00%
ETNB89bio, Inc. $14.84 +0.00% -12.82 $2.20B 0.00%
GLPGGalapagos N.V. $27.98 +1.71% 3.57 $1.84B 0.00%

About BEAM

BEAM stock trades at $25.62 with a market capitalization of $2.64B. The stock is valued at a price-to-earnings (P/E) ratio of -35.36, price-to-book of 2.38, price-to-sales of 17.96. Over the past 52 weeks the stock has ranged between $15.60 and $37.92, and currently trades 32.4% below its 52-week high.

On profitability, BEAM generates a return on equity (ROE) of -6.46%, return on capital employed of -31.02%, an operating margin of -274.29%, a net profit margin of -39.66%.

Related Healthcare Stocks

LLY Drug Manufacturers - General $1185.71 -0.52% JNJ Drug Manufacturers - General $259.24 +0.88% ABBV Drug Manufacturers - General $246.04 +0.89% UNH Medical - Healthcare Plans $407.08 +0.77% MRK Drug Manufacturers - General $128.57 +0.16% NVS Drug Manufacturers - General $158.83 -0.64% NVO Biotechnology $51.58 +1.22% TMO Medical - Diagnostics & Research $594.00 +2.41% AMGN Drug Manufacturers - General $387.64 -1.39% ABT Medical - Devices $108.03 +0.70% GILD Drug Manufacturers - General $132.73 -1.18% PFE Drug Manufacturers - General $26.74 +2.06%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksNasdaq High ROE StocksAll stock screens
Run Stock Screener Investing Guides